Johnson & Johnson $JNJ Shares Bought by Louisbourg Investments Inc.

Louisbourg Investments Inc. increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 42,112 shares of the company's stock after acquiring an additional 1,795 shares during the quarter. Johnson & Johnson makes up about 1.4% of Louisbourg Investments Inc.'s portfolio, making the stock its 25th biggest holding. Louisbourg Investments Inc.'s holdings in Johnson & Johnson were worth $6,433,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth approximately $35,000. Highline Wealth Partners LLC increased its stake in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the first quarter worth approximately $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson in the first quarter valued at approximately $48,000. Finally, von Borstel & Associates Inc. purchased a new position in Johnson & Johnson in the first quarter valued at approximately $49,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Price Performance

JNJ stock opened at $190.88 on Tuesday. The company has a market capitalization of $459.71 billion, a P/E ratio of 20.42, a PEG ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $192.10. The business has a 50 day simple moving average of $178.88 and a 200-day simple moving average of $163.97. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $24.02 billion during the quarter. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $209.00 price target on shares of Johnson & Johnson in a research note on Friday. Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. JPMorgan Chase & Co. increased their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research note on Tuesday, September 16th. Finally, Weiss Ratings upgraded shares of Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $192.94.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.